Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists

Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer

Actimed Therapeutics Expands Intellectual Property Portfolio

Actimed Therapeutics Appoints Dr Fabio Dorigotti as Chief Medical Officer to drive further pipeline development for cancer cachexia and other muscle wasting disorders

Actimed Therapeutics Announces Publication of Successful S-pindolol benzoate (ACM-001.1) Phase 1 Study in The Journal of Cachexia, Sarcopenia and Muscle

Actimed Therapeutics to Support 17th Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders

Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman

Actimed Therapeutics Announces US FDA Grant of Orphan Drug Designation to S-oxprenolol (ACM-002) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Actimed Therapeutics to Present at BioTrinity 2024

Actimed Therapeutics Appoints Martin Walton as Chief Financial Officer

Actimed Therapeutics announces FDA approval of its Investigational New Drug application for Phase 2b/3 IMPACT clinical trials of S-pindolol benzoate to treat cancer cachexia

Actimed Therapeutics secures additional £4.75m funding in Series A extension round, almost doubling Series A proceeds

Actimed Therapeutics closes over-subscribed Series A Financing Round of £5 million to advance clinical development of lead programme for cancer cachexia

Actimed Therapeutics Chief Medical Officer Frank Misselwitz Presents at 16th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders

Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders

Actimed Therapeutics to Present Company Progress at Biotech Showcase 2023 in San Francisco

Actimed Therapeutics to present on development of its lead asset in treatment of cancer cachexia at the Society on Sarcopenia, Cachexia and Wasting Disorders

Actimed Therapeutics’ Company participation and panel discussion at LSX World Congress 2022

Actimed Therapeutics secures significant new patent, extending IP coverage of its lead compound for use in key indication

Actimed Therapeutics to Participate at Biotech Showcase 2022

Actimed Therapeutics Achieves Major Corporate Milestone – Initiation of first clinical study of new salt of S-pindolol (ACM-001.1)

Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadian Patents

Actimed Therapeutics Announces Successful Closing of £2.5m Extended Seed B Funding Round

Actimed Therapeutics to Present at BioTrinity 2021

Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol

Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer

Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM–002 (S-oxprenolol) for Treating Cancer Cachexia

Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charité – Universitätsmedizin Berlin

Actimed Therapeutics to present at upcoming Bio-Europe conference as one of 'Scrip’s 10 to watch'

Actimed Therapeutics appoints Dr Chika Yoshinaga as Development, Partnering and Financing Advisor in Japan and China

Actimed Therapeutics appoints Annalisa Jenkins as Advisor

Actimed Therapeutics appoints Robin Bhattacherjee as CEO